down arrow

Alzamend Neuro, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US02262M4078
USD
2.25
0.1 (4.65%)

Dec 05

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.112.30

52 Week

1.8812.06
Valuation
Technical
Day's Volume

CASH

63.41 k

Shareholding (Jan 2025)

FII

0.00%

Held by 3 FIIs

DII

99.12%

Held by 1 DIIs

Promoter

0.00%

How big is Alzamend Neuro, Inc.?

22-Jun-2025

As of Jun 18, Alzamend Neuro, Inc. has a market capitalization of 2.38 million, with net sales of 0.00 million and a net profit of -4.22 million over the last four quarters. As of April 2024, the company's shareholder's funds were -2.59 million, and total assets were 0.63 million.

Market Cap: As of Jun 18, Alzamend Neuro, Inc. has a market capitalization of 2.38 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Alzamend Neuro, Inc. reported net sales of 0.00 million and a net profit of -4.22 million.<BR><BR>Balance Sheet Snapshot: As of April 2024, the company's shareholder's funds stood at -2.59 million, while total assets were recorded at 0.63 million.

Read More

What does Alzamend Neuro, Inc. do?

22-Jun-2025

Alzamend Neuro, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $1 million and a market cap of $2.38 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a debt-to-equity ratio of -0.97.

Overview:<BR>Alzamend Neuro, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: -1 Million (Quarterly Results - Jan 2025)<BR>- Market-cap: USD 2.38 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.97<BR>- Return on Equity: -148.10%<BR>- Price to Book: 0.69<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

Read More

Is Alzamend Neuro, Inc. technically bullish or bearish?

20-Sep-2025

As of August 4, 2025, Alzamend Neuro, Inc. shows a mildly bearish trend with mixed indicators, having returned 3.75% over the past week and 4.62% over the past month, but is down 76.15% year-to-date compared to the S&P 500's positive 12.22%.

As of 4 August 2025, the technical trend for Alzamend Neuro, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by mixed indicators: while the MACD and KST are mildly bullish on both weekly and monthly time frames, the moving averages are bearish on a daily basis. The RSI indicates bullish momentum on both weekly and monthly charts, but Bollinger Bands and OBV show a mildly bearish trend on the monthly. <BR><BR>In terms of performance, the stock has returned 3.75% over the past week and 4.62% over the past month, outperforming the S&P 500, which returned 1.05% and 2.33% respectively. However, the year-to-date return is significantly negative at -76.15%, compared to the S&P 500's positive 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 7 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.00

stock-summary
Return on Equity

-128.75%

stock-summary
Price to Book

1.72

Revenue and Profits:
Net Sales:
(Quarterly Results - Apr 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.02%
0%
-3.02%
6 Months
-39.52%
0%
-39.52%
1 Year
-78.26%
0%
-78.26%
2 Years
-97.6%
0%
-97.6%
3 Years
100.89%
0%
100.89%
4 Years
-99.92%
0%
-99.92%
5 Years
0%
0%
0.0%

Alzamend Neuro, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Alzamend Neuro, Inc. technically bullish or bearish?

As of 4 August 2025, the technical trend for Alzamend Neuro, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by mixed indicators: while the MACD and KST are mildly bullish on both weekly and monthly time frames, the moving averages are bearish on a daily basis. The RSI indicates bullish momentum on both weekly and monthly charts, but Bollinger Bands and OBV show a mildly bearish trend on the monthly. In terms of performance, the stock has returned 3.75% over the past week and 4.62% over the past month, outperforming the S&P 500, which returned 1.05% and 2.33% respectively. However, the year-to-date return is significantly negative at -76.15%, compared to the S&P 500's positive 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
-4.39
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.97
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.31%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.84
EV to EBIT
0.05
EV to EBITDA
0.05
EV to Capital Employed
-0.46
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-148.10%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jan 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.87%)

Foreign Institutions

Held by 3 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Apr 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is -22.22% vs 72.73% in Apr 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.10",
          "val2": "-0.80",
          "chgp": "-37.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.10",
          "val2": "-0.90",
          "chgp": "-22.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2025 is 0.00% vs 0.00% in Apr 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2025 is 54.55% vs 33.56% in Apr 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.40",
          "val2": "-9.90",
          "chgp": "55.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.50",
          "val2": "-9.90",
          "chgp": "54.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Apr'25 - YoYstock-summary
Apr'25
Apr'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.10
-0.80
-37.50%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.10
-0.90
-22.22%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Apr 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Apr 2025 is -22.22% vs 72.73% in Apr 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Apr'25stock-summary
Apr'25
Apr'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.40
-9.90
55.56%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.50
-9.90
54.55%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Apr 2025 is 0.00% vs 0.00% in Apr 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Apr 2025 is 54.55% vs 33.56% in Apr 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Alzamend Neuro, Inc. stock-summary
stock-summary
Alzamend Neuro, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."